PURPOSE: To present the effect of intravitreal ranibizumab (Lucentis®) therapy in a patient suffering from retinal macroaneurysm. METHODS: Case report. An 82-year-old female patient was diagnosed with retinal macroaneurysm of the inferior temporal artery with macular edema. Functional and morphological data at baseline and at 4 weeks, 3 months, and 5 months after the initiation of therapy with two intravitreal ranibizumab (Lucentis®) injections followed by focal argon laser coagulation surrounding the retinal macroaneurysm are presented. RESULTS: Best-corrected visual acuity improved from 20/50 at baseline to 20/20 at 3-month follow-up and maintained stable at 20/25 through 5-month follow-up. Central retinal thickness measured by optical coherence tomography decreased from 510 µm at baseline to 148 µm at 5-month follow-up. Fluorescein angiography demonstrated closure of the retinal macroaneurysm at 6-week follow-up. No ocular or systemic side effects were detected. CONCLUSIONS: Intravitreal ranibizumab (Lucentis®) therapy may close the retinal macroaneurysm leading to resolution of the associated macular edema and consequently visual improvement. To our knowledge, this is the first case of a retinal macroaneurysm benefiting from treatment with intravitreal ranibizumab (Lucentis®). The observed results warrant further investigation.
PURPOSE: To present the effect of intravitreal ranibizumab (Lucentis®) therapy in a patient suffering from retinal macroaneurysm. METHODS: Case report. An 82-year-old female patient was diagnosed with retinal macroaneurysm of the inferior temporal artery with macular edema. Functional and morphological data at baseline and at 4 weeks, 3 months, and 5 months after the initiation of therapy with two intravitreal ranibizumab (Lucentis®) injections followed by focal argon laser coagulation surrounding the retinal macroaneurysm are presented. RESULTS: Best-corrected visual acuity improved from 20/50 at baseline to 20/20 at 3-month follow-up and maintained stable at 20/25 through 5-month follow-up. Central retinal thickness measured by optical coherence tomography decreased from 510 µm at baseline to 148 µm at 5-month follow-up. Fluorescein angiography demonstrated closure of the retinal macroaneurysm at 6-week follow-up. No ocular or systemic side effects were detected. CONCLUSIONS: Intravitreal ranibizumab (Lucentis®) therapy may close the retinal macroaneurysm leading to resolution of the associated macular edema and consequently visual improvement. To our knowledge, this is the first case of a retinal macroaneurysm benefiting from treatment with intravitreal ranibizumab (Lucentis®). The observed results warrant further investigation.
Authors: Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Dante J Pieramici; Melvin Rabena; Alessandro A Castellarin; Ma'an Nasir; Robert See; Tamara Norton; Andres Sanchez; Sarah Risard; Robert L Avery Journal: Ophthalmology Date: 2008-08-16 Impact factor: 12.079
Authors: Carlos Menezes; Rui Carvalho; Carla Teixeira; José Alberto Lemos; Rita Gonçalves; Pedro Coelho; André Lima Journal: Case Rep Ophthalmol Date: 2015-06-02
Authors: Cristina Marín-Lambíes; Roberto Gallego-Pinazo; David Salom; Javier Navarrete; Manuel Díaz-Llopis Journal: Case Rep Ophthalmol Date: 2012-08-15